Recent News

• 05.15.2026 - TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
• 05.12.2026 - TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
• 04.22.2026 - TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
• 04.07.2026 - TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
• 04.01.2026 - TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
• 03.23.2026 - Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
• 02.27.2026 - TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent Filings

• 05.15.2026 - EX-99.1 EX-99.1
• 05.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2026 - 8-K Current report
• 04.30.2026 - 8-K/A Current report
• 04.30.2026 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.22.2026 - EX-99.1 EX-99.1
• 04.22.2026 - 8-K Current report
• 04.08.2026 - EX-99.1 EX-99.1
• 04.08.2026 - 8-K Current report
• 04.08.2026 - 424B5 Prospectus [Rule 424(b)(5)]